Aquestive Therapeutics (NASDAQ: AQST) has announced that the USPTO has issued two additional patents extending protection into 2037 for Anaphylm, a novel epinephrine prodrug sublingual film.
According to Aquestive, if approved by the FDA, Anaphylm will be the first and only oral medication for the treatment of severe allergic reactions, including anaphylaxis.
In a statement, Dan Barber, president and CEO of Aquestive, commented, “We are pleased with the issuance of these additional patents for Anaphylm, extending protection for the product through at least 2037. These claims cover the proprietary composition for Anaphlym, which enables the oral sublingual film delivery of an epinephrine prodrug. By leveraging our proprietary technology platforms, PharmFilm and Adrenaverse, in this inventive way, we are addressing significant unmet needs in severe allergic reactions, while reinforcing patent protection for Anaphylm. These patents are the result of a broad intellectual property strategy that includes many other multi-continent patent applications pending and planned.”
